Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Kallum Titchmarsh
MS
Kallum Titchmarsh
Morgan Stanley
Wall Street Analyst
★★★☆☆
#840
on 13Foresight · ranked by our own returns
65%
Success Rate
+4.5%
Average Return
20 of 31 calls profitable · -4.0% vs benchmark
📈 Across the calls we could measure, roughly 65% of Kallum Titchmarsh's ratings turned a profit when each position was held for 1 year — averaging +4.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

34 Buy 47 Hold 4 Sell
Kallum's Stock Coverage 30 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
IQV
IQVIA Holdings
 Jun 18, 2026 HOLD Strong Buy
+34.3% avg upside
38 analysts
$225.00
34.16% Upside
 ·
CRL
Charles River Labs
 Jun 18, 2026 BUY Strong Buy
+12.0% avg upside
34 analysts
$185.00
0.03% Upside
 ·
STVN
Stevanato Group
 Jun 10, 2026 HOLD Strong Buy
+54.2% avg upside
13 analysts
$19.00
8.35% Upside
 -0.7%
MMED
MiniMed Group, Inc.
 Jun 05, 2026 BUY Strong Buy
+48.5% avg upside
13 analysts
$19.00
28.73% Upside
 ·
WST
West Pharmaceutical Services
 May 29, 2026 HOLD Strong Buy
+6.5% avg upside
17 analysts
$325.00
0.89% Downside
 +2.1%
A
Agilent
 May 28, 2026 BUY Strong Buy
+3.9% avg upside
32 analysts
$160.00
25.98% Upside
 -2.0%
GH
Guardant Health
 May 27, 2026 BUY Strong Buy
-5.8% avg upside
30 analysts
$130.00
1.43% Downside
 +1.2%
HTFL
HeartFlow, Inc.
 May 15, 2026 HOLD Strong Buy
+9.2% avg upside
8 analysts
$35.00
4.09% Upside
 +8.3%
NTRA
Natera
 May 12, 2026 BUY Strong Buy
+7.6% avg upside
26 analysts
$250.00
8.06% Upside
 +10.9%
MTD
Mettler-Toledo
 May 12, 2026 HOLD Buy
+2.7% avg upside
18 analysts
$1275.00
11.34% Upside
 +7.6%
VCYT
Veracyte
 May 12, 2026 SELL Strong Buy
-19.0% avg upside
17 analysts
$37.00
30.96% Downside
 +2.7%
PSNL
Personalis
 May 12, 2026 HOLD Strong Buy
+13.8% avg upside
11 analysts
$9.00
14.57% Downside
 +74.5%
ADPT
Adaptive Biotechnologies
 May 12, 2026 HOLD Strong Buy
+20.0% avg upside
14 analysts
$18.00
2.76% Upside
 +29.1%
TXG
10x Genomics
 May 12, 2026 HOLD Buy
-26.8% avg upside
18 analysts
$22.00
36.76% Downside
 +51.8%
CTKB
Cytek Biosciences
 May 12, 2026 HOLD Buy
+49.2% avg upside
5 analysts
$5.50
45.91% Upside
 +3.7%
GRAL
GRAIL Inc
 May 12, 2026 HOLD Buy
+3.6% avg upside
8 analysts
$60.00
5.93% Downside
 -5.9%
TEM
Tempus AI, Inc. Class A
 May 12, 2026 BUY Strong Buy
+33.8% avg upside
19 analysts
$70.00
37.60% Upside
 +7.7%
WAT
Waters
 May 05, 2026 HOLD Strong Buy
+3.5% avg upside
30 analysts
$350.00
1.56% Downside
 +4.2%
TMO
Thermo Fisher
 Apr 27, 2026 BUY Strong Buy
+26.9% avg upside
38 analysts
$620.00
33.38% Upside
 -1.3%
DHR
Danaher
 Apr 23, 2026 BUY Strong Buy
+21.8% avg upside
45 analysts
$184.04
3.91% Upside
 -0.4%
AVTR
Avantor
 Feb 13, 2026 HOLD Buy
+49.6% avg upside
26 analysts
$10.00
4.41% Upside
 +4.7%
GMED
Globus Medical
 Jul 15, 2025 BUY Strong Buy
+22.3% avg upside
24 analysts
$68.00
14.11% Downside
 +43.9%
INSP
Inspire Medical Systems
 Jul 15, 2025 BUY Buy
+98.0% avg upside
20 analysts
$182.00
327.05% Upside
 -67.0%
IRTC
Irhythm Technologies
 Jun 11, 2025 BUY Strong Buy
+62.0% avg upside
19 analysts
$160.00
52.93% Upside
 -18.1%
EMBC
Embecta Corporation
 May 20, 2025 HOLD Sell
+146.5% avg upside
5 analysts
$15.00
382.39% Upside
 -73.0%
TMCI
Treace Medical Concepts
 May 09, 2025 HOLD Hold
+28.4% avg upside
8 analysts
$10.00
138.74% Upside
 -73.9%
SIBN
SI-Bone
 May 06, 2025 BUY Strong Buy
+60.9% avg upside
18 analysts
$19.00
19.91% Upside
 -21.0%
PEN
Penumbra
 Apr 24, 2025 HOLD Buy
+4.5% avg upside
23 analysts
$260.00
18.01% Downside
 +10.6%
ATEC
Alphatec Holdings
 Feb 27, 2025 HOLD Strong Buy
+116.6% avg upside
22 analysts
$11.00
24.93% Upside
 +12.4%
SGHT
Sight Sciences
 Dec 03, 2024 HOLD Buy
+54.1% avg upside
13 analysts
$4.00
24.15% Downside
 +121.8%
🔒 25 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Kallum Titchmarsh — Frequently Asked Questions
How accurate are Kallum Titchmarsh's stock ratings?
Based on the calls 13Foresight could measure, about 68% of Kallum's ratings were profitable over a one-year hold, with an average return of +4.6% per rating, or -3.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Kallum ranked on 13Foresight?
Kallum Titchmarsh is currently ranked #840 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Kallum cover?
Kallum most recently has ratings on IQV, CRL, STVN, MMED, WST, A, GH, HTFL, NTRA, MTD, VCYT, PSNL and 18 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.